After deliberating for fewer than six hours, a New Jersey jury returned a 7-to-1 verdict in favor of Novartis Pharmaceuticals Corporation in a thirteen-day trial involving Zometa, a bisphosphonate drug given to cancer patients suffering metastases…
After deliberating for fewer than forty-five minutes, a federal jury in Tampa, Florida returned a unanimous verdict in favor of Novartis Pharmaceuticals Corporation in a 3-week trial involving Aredia and Zometa, bisphosphonate medicines used to treat…
In two opinions issued by the U.S. District Court for the District of Columbia, the Court dismissed claims brought by 3,200 individual Ecuadorian plaintiffs against DynCorp International for alleged crop, animal and human health damages and…
Judge Henry L. Adams granted the motion of Novartis Pharmaceuticals Corporation (“NPC”) to apply New Jersey punitive damages law in a pharmaceutical products liability lawsuit filed in the Middle District of Florida by a Florida resident…
Chief Judge Mary Lisi of the U.S. District Court for the District of Rhode Island adopted Magistrate Judge Lincoln Almond’s recommendation and entered judgment in favor of Novartis in Patterson v. Novartis Pharm. Corp., No. 1:11-402-ML-LDA…
Judge Roger Titus of the U.S. District Court for the District of Maryland granted summary judgment in favor of Novartis Pharmaceuticals Corporation in a case alleging that plaintiff’s treatment with Novartis’s drugs Aredia and Zometa caused osteonecrosis…
The U.S. District Court for the Eastern District of Washington granted Novartis Pharmaceuticals Corporation’s Daubert motion and so excluded plaintiff’s expert witnesses and then granted summary judgment in favor of Novartis in Luttrell v. Novartis Pharm.…
After two and a half days of trial, the plaintiff in Brown v. Novartis Pharm. Corp., No. 7:08-CV-00130-FL (E.D.N.C.), agreed to dismiss with prejudice his claims against Firm client Novartis Pharmaceuticals Corporation (“NPC”). The plaintiff is…
The U.S. District Court for the Eastern District of Texas granted Novartis Pharmaceuticals Corporation’s motion to strike the purported alternative design declaration of MDL-wide expert Dr. Robert Marx, and then granted summary judgment in favor of…
Zimmerman v. Novartis Pharm. Corp., No. 8:08-cv-02089-RWT (D. Md. Sept, 5, 2012)
The Second Circuit affirmed a defense verdict in Hogan v. Novartis Pharm. Corp., 1:06-260-BMC (E.D.N.Y.). On appeal, plaintiff/appellant argued that the district court erred in denying her last-minute request to present testimony from a treating oral…
Ingram v. Novartis Pharm. Corp., 888 F. Supp. 2d 1241 (W.D. Okla. 2012)
The U.S. District Court for the Eastern District of Missouri granted Novartis Pharmaceuticals Corporation’s Daubert motion regarding plaintiff’s expert witnesses and then granted summary judgment in favor of Novartis in Parmentier (Johnson) v. Novartis Pharm. Corp., No.…
The New Jersey Appellate Division affirmed judgment in favor of Novartis Pharmaceuticals Corporation, rejecting plaintiffs’ appeal of a 2010 defense verdict in the first bellwether trial arising out of the Aredia/Zometa consolidated litigation in New Jersey…
Judge Graham Mullen ruled on Novartis’s Daubert motion in a Zometa case, excluding large portions of the opinions of Dr. Suzanne Parisian. Lemons v. Novartis Pharm. Corp., No. 3:08-cv-00361 (W.D.N.C. Order March 21, 2012). Dr. Parisian…
